Skip to main content

Neurology

3 drugs are in development for Pompe Disease.

Companies
3
Clinical trials
12
BioSniper AIPage evidence connected

Prepared research question

Which programs lead the Pompe Disease pipeline—and what evidence could change the picture?

Run cited research

Traceable citations · Unknowns marked

Drug Pipeline by Phase

Phase 1(1)
Preclinical(1)
About this indication

Pompe Disease context

Neurology·MeSH: Glycogen Storage Disease Type II (D006009)

Also known as: Acid Alpha Glucosidase Deficiency, Acid Alpha-Glucosidase Deficiencies, Acid Maltase Deficiency Disease, Alpha-Glucosidase Deficiencies, Alpha-Glucosidase Deficiency, Deficiencies, GAA, Deficiency Disease, Lysosomal alpha-1,4-Glucosidase, Deficiency of Alpha Glucosidase, Deficiency, GAA, Disease, Pompe's, GSD II, GSD2, GSD2s, Generalized Glycogenoses, Glycogen Storage Disease II, Glycogen Storage Disease Type 2, Glycogen Storage Disease Type II, Glycogenosis 2, Glycogenosis, Generalized, Lysosomal alpha 1,4 Glucosidase Deficiency Disease, Type II, Glycogenosis, Type IIs, Glycogenosis

Incidence

0.3 / 100K/yr

Frequently asked questions

How many drugs are in development for Pompe Disease?

BioSniper tracks 3 drugs in development for Pompe Disease across 3 companies.

How many clinical trials target Pompe Disease?

There are 12 clinical trials targeting Pompe Disease tracked by BioSniper.